Coffee reduces ovarian cancer: Caffeine may reduce the risk of ovarian cancer, particularly in women who do not use hormones, according to the March 1 journal CANCER, which revealed findings of Shelley S. Tworoger, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, et al. "The potential reduction in risk with higher caffeine intake appeared to be strongest for women who had never used oral contraceptives or postmenopausal hormones," an abstract of the study notes. Researchers also found cigarette smoking may only increase the risk for mucinous ovarian tumors, and alcohol intake is not associated with risk. Researchers gleaned data from questionnaires from the Nurses' Health Study, examining associations between caffeine or alcohol and ovarian cancer risk among 80,253 women between 1976 and 2004. Tworoger, et al. claim more research is needed...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
